BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/21/2024 7:25:52 AM | Browse: 139 | Download: 686
 |
Received |
|
2023-12-12 13:47 |
|
Peer-Review Started |
|
2023-12-12 13:47 |
|
First Decision by Editorial Office Director |
|
2024-03-09 20:18 |
|
Return for Revision |
|
2024-03-09 20:18 |
|
Revised |
|
2024-03-22 15:49 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-04-17 02:30 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-04-17 07:50 |
|
Articles in Press |
|
2024-04-17 07:50 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-04-26 10:19 |
|
Publish the Manuscript Online |
|
2024-05-21 07:25 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Editorial |
| Article Title |
Bruton’s tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Leonardo S Lino-Silva, Sabrina B Martínez-Villavicencio and Luisa F Rivera-Moncada |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Leonardo S Lino-Silva, MSc, Director, Director, Professor, Senior Researcher, Department of Pathology Oncology, National Cancer Institute (Mexico), Av. San fernando 22, Sección XVI, Tlalpan, Mexico City 14080, Mexico. saul.lino.sil@gmail.com |
| Key Words |
Primary central nervous system lymphoma; Zanubrutinib; Bruton’s tyrosine kinase; Prognosis; Myeloid differentiation primary response 88 gene; Cluster of differentiation 79B gene |
| Core Tip |
The combination of zanubrutinib with high-dose methotrexate shows promise as a therapeutic approach for primary central nervous system lymphoma (PCNSL). In this study involving 19 patients, the treatment demonstrated a notable 84.2% overall response rate with manageable adverse events. The presence of circulating tumor DNA in cerebrospinal fluid emerged as a potential tool for monitoring treatment response. These findings are optimistic, but research in larger patient groups is crucial to validate outcomes and assess long-term effects, especially in different molecular subtypes of PCNSL. |
| Publish Date |
2024-05-21 07:25 |
| Citation |
Lino-Silva LS, Martínez-Villavicencio SB, Rivera-Moncada LF. Bruton’s tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon. World J Clin Oncol 2024; 15(5): 587-590 |
| URL |
https://www.wjgnet.com/2218-4333/full/v15/i5/587.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v15.i5.587 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
